Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The role of fMRI in drug development.
Carmichael O, Schwarz AJ, Chatham CH, Scott D, Turner JA, Upadhyay J, Coimbra A, Goodman JA, Baumgartner R, English BA, Apolzan JW, Shankapal P, Hawkins KR. Carmichael O, et al. Among authors: english ba. Drug Discov Today. 2018 Feb;23(2):333-348. doi: 10.1016/j.drudis.2017.11.012. Epub 2017 Nov 15. Drug Discov Today. 2018. PMID: 29154758 Free PMC article. Review.
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE).
Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Tack J. Chang L, et al. Among authors: english ba. Neurogastroenterol Motil. 2023 May;35(5):e14539. doi: 10.1111/nmo.14539. Epub 2023 Feb 5. Neurogastroenterol Motil. 2023. PMID: 36740814 Clinical Trial.
Safety, Pharmacokinetics, and Efficacy of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, in a Phase 2a Study of Patients With Chronic Abdominal Pain Associated With Crohn's Disease.
Yacyshyn BR, Hanauer S, Klassen P, English BA, Stauber K, Barish CF, Gilder K, Turner S, Higgins PDR. Yacyshyn BR, et al. Among authors: english ba. Crohns Colitis 360. 2020 Oct 24;3(1):otaa089. doi: 10.1093/crocol/otaa089. eCollection 2021 Jan. Crohns Colitis 360. 2020. PMID: 36777064 Free PMC article.
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Fava M, et al. Among authors: english ba. Mol Psychiatry. 2016 Oct;21(10):1483-4. doi: 10.1038/mp.2016.140. Epub 2016 Aug 16. Mol Psychiatry. 2016. PMID: 27528461 Free PMC article. No abstract available.
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. Fava M, et al. Among authors: english ba. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Mol Psychiatry. 2016. PMID: 26643541 Free PMC article. Clinical Trial.
Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise.
Kohli U, Diedrich A, Kannankeril PJ, Muszkat M, Sofowora GG, Hahn MK, English BA, Blakely RD, Stein CM, Kurnik D. Kohli U, et al. Among authors: english ba. Physiol Genomics. 2015 Sep;47(9):400-6. doi: 10.1152/physiolgenomics.00124.2014. Epub 2015 Jun 9. Physiol Genomics. 2015. PMID: 26058836 Free PMC article.
25 results